These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 29309286)

  • 1. The paradox of clopidogrel use in patients with acute coronary syndromes and diabetes: insight from the Diabetes and Acute Coronary Syndrome Registry.
    Ferlini M; Musumeci G; Grieco N; Rossini R; De Servi S; Mafrici A; Sponzilli C; Demarchi A; Assanelli EM; Camisasca P; Chizzola G; Corrada E; Farina A; Pedrinazzi C; Lettieri C; Oltrona Visconti L
    Coron Artery Dis; 2018 Jun; 29(4):309-315. PubMed ID: 29309286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of diabetic patients hospitalized for acute coronary syndromes: a prospective multicenter registry.
    Ferlini M; Musumeci G; Demarchi A; Grieco N; Mafrici A; De Servi S; Rossini R; Sponzilli C; Bognetti P; Cardile A; Frattini S; Ielasi A; Russo A; Vecchiato C; Lettieri C; Visconti LO
    J Cardiovasc Med (Hagerstown); 2017 Aug; 18(8):572-579. PubMed ID: 28590305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative.
    Faridi KF; Garratt KN; Kennedy KF; Maddox TM; Secemsky EA; Butala NM; Yeh RW
    Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e006275. PubMed ID: 32156164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes.
    Esteve-Pastor MA; Ruíz-Nodar JM; Orenes-Piñero E; Rivera-Caravaca JM; Quintana-Giner M; Véliz-Martínez A; Tello-Montoliu A; PerniasEscrig V; Sandín Rollán M; Vicente-Ibarra N; MacíasVillanego MJ; Candela Sánchez E; Carrillo Alemán L; Lozano T; Valdés M; Marín F
    J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):57-65. PubMed ID: 28789568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients.
    Gager GM; Jilma B; Winter MP; Hengstenberg C; Lang IM; Toma A; Prüller F; Wallner M; Kolesnik E; von Lewinski D; Siller-Matula JM
    Eur J Clin Invest; 2020 Nov; 50(11):e13304. PubMed ID: 32506444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Did Prasugrel and Ticagrelor Offer the Same Benefit in Patients with Acute Coronary Syndromes after Percutaneous Coronary Interventions Compared to Clopidogrel? Insights from Randomized Clinical Trials, Registries and Meta-analysis.
    Rodriguez AE; Rodriguez-Granillo AM; Ascarrunz SD; Peralta-Bazan F; Cho MY
    Curr Pharm Des; 2018; 24(4):465-477. PubMed ID: 29308737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
    Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
    Gimbel M; Qaderdan K; Willemsen L; Hermanides R; Bergmeijer T; de Vrey E; Heestermans T; Tjon Joe Gin M; Waalewijn R; Hofma S; den Hartog F; Jukema W; von Birgelen C; Voskuil M; Kelder J; Deneer V; Ten Berg J
    Lancet; 2020 Apr; 395(10233):1374-1381. PubMed ID: 32334703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetic patients with acute coronary syndromes in contemporary European registries: characteristics and outcomes.
    Lettino M; Andell P; Zeymer U; Widimsky P; Danchin N; Bardaji A; Barrabes JA; Cequier A; Claeys MJ; De Luca L; Dörler J; Erlinge D; Erne P; Goldstein P; Koul SM; Lemesle G; Lüscher TF; Matter CM; Montalescot G; Radovanovic D; Sendón JL; Tousek P; Weidinger F; Weston CFM; Zaman A; Li J; Jukema JW;
    Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):198-213. PubMed ID: 28329196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention.
    Faggioni M; Baber U; Chandrasekhar J; Sartori S; Claessen BE; Rao SV; Vogel B; Effron MB; Poddar K; Farhan S; Kini A; Weintraub W; Toma C; Sorrentino S; Weiss S; Snyder C; Muhlestein JB; Kapadia S; Keller S; Strauss C; Aquino M; Baker B; Defranco A; Pocock S; Henry T; Mehran R
    Int J Cardiol; 2019 Jan; 275():31-35. PubMed ID: 30391067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry.
    Basra SS; Wang TY; Simon DN; Chiswell K; Virani SS; Alam M; Nambi V; Denktas AE; Deswal A; Bozkurt B; Ballantyne CM; Peterson ED; Jneid H
    J Am Heart Assoc; 2018 Jun; 7(12):. PubMed ID: 29886424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year efficacy and safety of prasugrel and ticagrelor in patients with acute coronary syndromes: Results from a prospective and multicentre ACHILLES registry.
    Ruiz-Nodar JM; Esteve-Pastor MA; Rivera-Caravaca JM; Sandín M; Lozano T; Vicente-Ibarra N; Orenes-Piñero E; Macías MJ; Pernías V; Carrillo L; Candela E; Veliz A; Tello-Montoliu A; Martínez Martínez JG; Marín F
    Br J Clin Pharmacol; 2020 Jun; 86(6):1052-1061. PubMed ID: 31912949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-Plus Registry.
    Kurz DJ; Radovanovic D; Seifert B; Bernheim AM; Roffi M; Pedrazzini G; Windecker S; Erne P; Eberli FR
    Eur Heart J Acute Cardiovasc Care; 2016 Feb; 5(1):13-22. PubMed ID: 25614494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Ischemic and Bleeding Risk Scores and the Use of New P2Y
    Flores-Blanco PJ; Cambronero-Sánchez F; Raposeiras-Roubin S; Abu-Assi E; Leithold G; Cobas-Paz R; Rodríguez Serrano AI; Calvo-Iglesias F; Valdés M; Januzzi JL; Iñiguez-Romo A; Manzano-Fernández S
    Rev Esp Cardiol (Engl Ed); 2018 Jul; 71(7):538-544. PubMed ID: 29146484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescription Patterns of Clopidogrel, Prasugrel, and Ticagrelor After Percutaneous Coronary Intervention With Stent Implantation (from the NCDR PINNACLE Registry).
    Khalid U; Bandeali S; Jones PG; Virani SS; Hira R; Hamzeh I; Chan PS; Kleiman NS; Lakkis N; Alam M
    Am J Cardiol; 2019 Dec; 124(12):1807-1812. PubMed ID: 31668345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy.
    Verdoia M; Pergolini P; Nardin M; Rolla R; Negro F; Kedhi E; Suryapranata H; Marcolongo M; Carriero A; De Luca G;
    Vascul Pharmacol; 2019 Sep; 120():106564. PubMed ID: 31176855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world clopidogrel utilization in acute coronary syndromes: patients selection and outcomes in a single-center experience.
    Castini D; Persampieri S; Cazzaniga S; Ferrante G; Centola M; Lucreziotti S; Salerno-Uriarte D; Sponzilli C; Carugo S
    Ther Adv Cardiovasc Dis; 2017 Dec; 11(12):323-331. PubMed ID: 29134853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors.
    Ristorto J; Messas N; Marchandot B; Kibler M; Hess S; Meyer N; Schaeffer M; Tuzin N; Ohlmann P; Jesel L; Morel O
    J Atheroscler Thromb; 2018 Aug; 25(8):674-689. PubMed ID: 29415954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends for and Clinical Factors Associated with Choice of Oral P2Y
    Jain N; Hunt SL; Cui H; Phadnis MA; Mahnken JD; Shireman TI; Dai J; Mehta JL; Rasu RS
    Cardiovasc Drugs Ther; 2019 Oct; 33(5):511-521. PubMed ID: 31729588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current patterns of antithrombotic and revascularisation therapy in patients hospitalised for acute coronary syndromes. Data from the Polish subset of the EPICOR study.
    Wojtkowska I; Stępińska J; Stępień-Wojno M; Sobota M; Kopaczewski J; Reszka Z; Kurzelewski M; Medina J
    Kardiol Pol; 2017; 75(5):445-452. PubMed ID: 28281731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.